|
1
|
Hashimoto M, Itonaga H, Nannya Y, Taniguchi H, Fukuda Y, Furumoto T, Fujioka M, Kasai S, Taguchi M, Taniguchi H, Sato S, Sawayama Y, Atogami S, Iwasaki K, Hata T, Soda H, Moriuchi Y, Nakata K, Ogawa S, Miyazaki Y. Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome. Intern Med 2020; 59:1081-1086. [PMID: 31875636 PMCID: PMC7205539 DOI: 10.2169/internalmedicine.3770-19] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Secondary pulmonary alveolar proteinosis (sPAP) is a complication of myelodysplastic syndrome (MDS). A 60-year-old woman was diagnosed with MDS with excess blasts-1. Fifty-four months after the initial diagnosis, treatment with azacitidine was initiated. Seventy-three months after the diagnosis, a bone marrow examination revealed increased myeloblasts, at which time computed tomography showed diffuse ground-glass opacities and interlobular septal thickening in the bilateral lower lung fields. A lung biopsy revealed the presence of PAP; therefore, the clinical diagnosis of MDS/sPAP was confirmed. Careful attention should be paid to the development of sPAP in MDS patients with pulmonary lesions during azacitidine treatment.
Collapse
Affiliation(s)
- Miki Hashimoto
- Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan
| | - Hidehiro Itonaga
- Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan
| | - Yasuhito Nannya
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan
| | - Hirokazu Taniguchi
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
| | - Yuichi Fukuda
- Department of Respiratory Medicine, Sasebo City General Hospital, Japan
| | | | - Machiko Fujioka
- Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan
- Department of Hematology, Nagasaki University Hospital, Japan
| | - Sachie Kasai
- Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan
| | | | | | - Shinya Sato
- Department of Hematology, Nagasaki University Hospital, Japan
| | | | - Sunao Atogami
- Department of Clinical Laboratory, Sasebo City General Hospital, Japan
| | - Keisuke Iwasaki
- Department of Pathology, Sasebo City General Hospital, Japan
| | - Tomoko Hata
- Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan
| | - Hiroshi Soda
- Department of Respiratory Medicine, Sasebo City General Hospital, Japan
| | | | - Koh Nakata
- Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Japan
| | - Seishi Ogawa
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan
| | - Yasushi Miyazaki
- Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan
- Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan
- Department of Hematology, Nagasaki University Hospital, Japan
| |
Collapse
|